Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

被引:17
|
作者
Li, Wei-ming [1 ]
Zhao, Yi-fan [1 ]
Zhu, Guo-fu [1 ]
Peng, Wen-hui [1 ]
Zhu, Meng-yun [1 ]
Yu, Xue-jing [1 ]
Chen, Wei [1 ]
Xu, Da-chun [1 ]
Xu, Ya-wei [1 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cardiol, Sch Med, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
cardiac hypertrophy; dual specific phosphatase 12; c-Jun N-terminal kinase (JNK); signalling pathway; SP600125; N-TERMINAL KINASE; HEART-FAILURE; ACTIVATION; REGULATORS; CARDIOMYOPATHY; IDENTIFICATION; APOPTOSIS; REVEALS; BINDING; ERK1/2;
D O I
10.1042/CS20160664
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase (DUSP) family, which is characterized by its DUSP activity to dephosphorylate both tyrosine and serine/threonine residues on one substrate. Some DUSPs have been identified as being involved in the regulation of cardiac hypertrophy. However, the role of DUSP12 during pathological cardiac hypertrophy is still unclear. In the present study, we observed a significant decrease in DUSP12 expression in hypertrophic hearts and cardiomyocytes. Using a genetic loss-of-function murine model, we demonstrated that DUSP12 deficiency apparently aggravated pressure overload-induced cardiac hypertrophy and fibrosis as well as impaired cardiac function, whereas cardiac-specific overexpression of DUPS12 was capable of reversing this hypertrophic and fibrotic phenotype and improving contractile function. Furthermore, we demonstrated that JNK1/2 activity but neither ERK1/2 nor p38 activity was increased in the DUSP12 deficient group and decreased in the DUSP12 overexpression group both in vitro and in vivo under hypertrophic stress conditions. Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice. DUSP12 protects against pathological cardiac hypertrophy and related pathologies. This regulatory role of DUSP12 is primarily through c-Jun N-terminal kinase (JNK) inhibition. DUSP12 could be a promising therapeutic target of pathological cardiac hypertrophy. DUSP12 is down-regulated in hypertrophic hearts. An absence of DUSP12 aggravated cardiac hypertrophy, whereas cardiomyocyte-specific DUSP12 overexpression can alleviate this hypertrophic phenotype with improved cardiac function. Further study demonstrated that DUSP12 inhibited JNK activity to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 50 条
  • [1] Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
    Norden, Einar Sjaastad
    Bendiksen, Bard Andre
    Andresen, Henriette
    Bergo, Kaja Knudsen
    Espe, Emil Knut
    Hasic, Almira
    Hauge-Iversen, Ida Marie
    Veras, Ioanni
    Hussain, Rizwan I.
    Sjaastad, Ivar
    Christensen, Geir
    Cataliotti, Alessandro
    ESC HEART FAILURE, 2021, 8 (02): : 918 - 927
  • [2] Parkin Contributes to the Development of Cardiac Hypertrophy in Response to Cardiac Pressure Overload
    Shires, Sarah E.
    Kubli, Dieter A.
    Gonzalez, Eileen R.
    Purcell, Nicole H.
    Gustafsson, Asa B.
    CIRCULATION RESEARCH, 2015, 117
  • [3] Rutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II
    Li, Shujun
    Huang, Bo
    Zhou, Changfei
    Shi, Jingshan
    Wu, Qin
    Jiang, Qingsong
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [4] Midkine Exacerbates Cardiac Hypertrophy and Remodeling in Response to Pressure Overload
    Netsu, Shunsuke
    Shishido, Tetsuro
    Ishino, Mitsunori
    Kadowaki, Shinpei
    Narumi, Taro
    Otaki, Yoichiro
    Funayama, Akira
    Honda, Shintaro
    Hasegawa, Hiromasa
    Nishiyama, Satoshi
    Takahashi, Hiroki
    Arimoto, Takanori
    Miyashita, Takehiko
    Miyamoto, Takuya
    Watanabe, Tetsu
    Kubota, Isao
    CIRCULATION, 2011, 124 (21)
  • [5] Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis
    Tang, Chaoliang
    Yin, Guobing
    Huang, Chunxia
    Wang, Hongtao
    Gao, Jie
    Luo, Jianfeng
    Zhang, Zhetao
    Wang, Jiawu
    Hong, Junmou
    Chai, Xiaoqing
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [6] Chlorogenic Acid Ameliorates Pressure Overload-Induced Cardiac Hypertrophy in Mouse Models
    Morio, Atsushi
    Satomi, Shiho
    Miyoshi, Hirotsugu
    Toyota, Yukari
    Tsustumi, Yasuo M.
    CIRCULATION, 2021, 144
  • [7] Cardiac hypertrophy is enhanced in PPARα-/- mice in response to chronic pressure overload
    Smeets, Pascal J. H.
    Teunissen, Birgit E. J.
    Willemsen, Peter H. M.
    van Nieuwenhoven, Frans A.
    Brouns, Agnieszka E.
    Janssen, Ben J. A.
    Cleutjens, Jack P. M.
    Staels, Bart
    van der Vusse, Ger J.
    van Bilsen, Marc
    CARDIOVASCULAR RESEARCH, 2008, 78 (01) : 79 - 89
  • [8] Grb2 regulates cardiac hypertrophy in response to pressure overload
    Zhang, SS
    Ye, L
    Muslin, AJ
    CIRCULATION, 2001, 104 (17) : 84 - 85
  • [9] Cardiac hypertrophy in response to pressure overload and exercise training in the American alligator
    Owerkowicz, T.
    Campbell, C.
    Eme, J.
    Blank, J. M.
    Hicks, J. W.
    INTEGRATIVE AND COMPARATIVE BIOLOGY, 2012, 52 : E132 - E132
  • [10] Role of Gα12/13 in pressure overload-induced cardiac hypertrophy
    Nishihara, N
    Sato, Y
    Kawano, S
    Kubota, T
    Kobayashi, H
    Nishida, M
    Kurose, H
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 136P - 136P